148 related articles for article (PubMed ID: 20947311)
1. Antiviral activity of 5'-O-carbonate-2',3'-dideoxy-3'-thiacytidine prodrugs against hepatitis B virus in HepG2 2.2.15 cells.
Gagey D; Ravetti S; Castro EF; Gualdesi MS; Briñon MC; Campos RH; Cavallaro LV
Int J Antimicrob Agents; 2010 Dec; 36(6):566-9. PubMed ID: 20947311
[TBL] [Abstract][Full Text] [Related]
2. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.
Delaney WE; Miller TG; Isom HC
Antimicrob Agents Chemother; 1999 Aug; 43(8):2017-26. PubMed ID: 10428929
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and anti-HIV activity of novel 2',3'-dideoxy-3'-thiacytidine prodrugs.
Ravetti S; Gualdesi MS; Trinchero-Hernández JS; Turk G; Briñón MC
Bioorg Med Chem; 2009 Sep; 17(17):6407-13. PubMed ID: 19660957
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and human hepatitis B virus (HBV) replication.
Srivastav NC; Shakya N; Mak M; Agrawal B; Tyrrell DL; Kumar R
J Med Chem; 2010 Oct; 53(19):7156-66. PubMed ID: 20857959
[TBL] [Abstract][Full Text] [Related]
5. Potent nonclassical nucleoside antiviral drugs based on the N,N-diarylformamidine concept.
Anastasi C; Hantz O; De Clercq E; Pannecouque C; Clayette P; Dereuddre-Bosquet N; Dormont D; Gondois-Rey F; Hirsch I; Kraus JL
J Med Chem; 2004 Feb; 47(5):1183-92. PubMed ID: 14971898
[TBL] [Abstract][Full Text] [Related]
6. Are 5'-O-carbamate-2',3'-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs?
Anastasi C; Vlieghe P; Hantz O; Schorr O; Pannecouque C; Witvrouw M; De Clercq E; Clayette P; Dereuddre-Bosquet N; Dormont D; Gondois-Rey F; Hirsch I; Kraus JL
Bioorg Med Chem Lett; 2003 Aug; 13(15):2459-63. PubMed ID: 12852943
[TBL] [Abstract][Full Text] [Related]
7. Differential inhibition of lamivudine-resistant hepatitis B virus by allele-specific RNAi.
Teng X; Xu WZ; Hao ML; Fang Y; Zhao YX; Chen SJ; Li D; Gu HX
J Virol Methods; 2010 Sep; 168(1-2):6-12. PubMed ID: 20403386
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication.
Yang J; Bo XC; Ding XR; Dai JM; Zhang ML; Wang XH; Wang SQ
J Viral Hepat; 2006 Mar; 13(3):158-65. PubMed ID: 16475991
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the replication of hepatitis B virus in vitro by emodin.
Shuangsuo D; Zhengguo Z; Yunru C; Xin Z; Baofeng W; Lichao Y; Yan'an C
Med Sci Monit; 2006 Sep; 12(9):BR302-6. PubMed ID: 16940925
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.
Vincent IE; Lucifora J; Durantel D; Hantz O; Chemin I; Zoulim F; Trepo C
Antivir Ther; 2009; 14(1):131-5. PubMed ID: 19320247
[TBL] [Abstract][Full Text] [Related]
11. Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication.
Kumar R; Semaine W; Johar M; Tyrrell DL; Agrawal B
J Med Chem; 2006 Jun; 49(12):3693-700. PubMed ID: 16759112
[TBL] [Abstract][Full Text] [Related]
12. [Anti-hepatitis B virus effects of lamivudine and other five drugs in vitro].
Cao H; Tao P
Zhonghua Yi Xue Za Zhi; 2001 Aug; 81(16):1004-7. PubMed ID: 11718074
[TBL] [Abstract][Full Text] [Related]
13. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
van der Eijk AA; Hansen BE; Niesters HG; Janssen HL; van de Ende M; Schalm SW; de Man RA
J Viral Hepat; 2005 Jul; 12(4):364-72. PubMed ID: 15985006
[TBL] [Abstract][Full Text] [Related]
14. In vitro anti-hepatitis B virus activities of 5"-O-myristoyl analogue derivatives of 3"-fluoro-2",3"-dideoxythymidine (FLT) and 3"-azido-2",3"-dideoxythymidine (AZT).
Parang K; Wiebe LI; Knaus EE; Huang JS; Tyrrell DL
J Pharm Pharm Sci; 1998; 1(3):108-14. PubMed ID: 10948398
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of hepatitis B virus replication by the internal fragment of hepatitis B core protein.
Han J; Pan X; Gao Y; Weil L
Virus Res; 2010 Jun; 150(1-2):129-34. PubMed ID: 20303370
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro.
Colledge D; Locarnini S; Shaw T
Hepatology; 1997 Jul; 26(1):216-25. PubMed ID: 9214473
[TBL] [Abstract][Full Text] [Related]
17. Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs.
Ding XR; Yang J; Sun DC; Lou SK; Wang SQ
Pharmacogenomics J; 2008 Feb; 8(1):61-70. PubMed ID: 17505500
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and antiviral activity in hepatitis B-and HIV-1-infected cells.
Xie H; Voronkov M; Liotta DC; Korba BA; Schinazi RF; Richman DD; Hostetler KY
Antiviral Res; 1995 Oct; 28(2):113-20. PubMed ID: 8585765
[TBL] [Abstract][Full Text] [Related]
19. Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine.
Zhu YL; Dutschman DE; Liu SH; Bridges EG; Cheng YC
Antimicrob Agents Chemother; 1998 Jul; 42(7):1805-10. PubMed ID: 9661025
[TBL] [Abstract][Full Text] [Related]
20. [In vitro evaluation on the effects of combined lamivudine (3TC) and Ara-AMP against hepatitis B virus].
Su H; Wang H; Ji W; Zhao Y; Cai G
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Mar; 16(1):16-9. PubMed ID: 11986737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
